TANG CAPITAL ACQUISITION CORP.

Tang Capital Acquisition Corp. filed an S-1 for a $75 million IPO of 3,000,000 ordinary shares at $25.00 per share, targeting a business combination in the biopharmaceutical industry. The company bills itself as the first "no-promote" SPAC (np-SPAC): no founder shares, no Class B shares, and no sponsor warrants — every sponsor share is purchased at the same $25.00 price as public investors. The sponsor has indicated a non-binding intention to purchase 2,000,000 shares (67% of the offering) for $50 million. The completion window is a fixed 24 months with no extensions, and 100% of gross IPO

Price data unavailable.

This is a structural experiment in SPAC design — eliminating the traditional 20% promote that has been the central investor grievance and regulatory target in the SPAC boom-and-bust cycle.

This filing introduces a novel SPAC structure — the np-SPAC — eliminating the traditional 20% founder promote that has drawn regulatory and investor scrutiny. If successful, it could pressure conventional SPAC sponsors to reduce or eliminate promotes, particularly in biopharma where Tang Capital's $

Sponsor's non-binding indication to purchase 67% of shares is not a legal commitment — if the sponsor buys fewer shares, the trust and dilution economics shift. The management team has no prior SPAC experience, and an affiliated business combination with Tang Capital entities creates inherent self‑t